Teva to Buy Allergan Generics

Teva Pharmaceutical Industries Ltd. is an international pharmaceutical company headquartered in Israel. It specializes in primarily in generic drugs. It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide. The Industry has agreed to buy Allergan generic drugs business for $40.5 Billion.

Allergan generic business is generally seen as a better fit than Teva previous target Mylan because it will improve Teva distribution channels and because Allergan is strong in bio similar drugs. At the same time, Teva dropped its $40 Billion bid for Mylan, which hit a snag when a Dutch foundation linked to Mylan bought temporarily control of half the company in an attempt to block the takeover.

Allergan Generic is expected to contribute about $2.7 Billion in earnings before interest, taxes, and other items next year. Following the completion of the acquisition, Teva is expected to have pro forma sales of approximately $26 Billion worldwide and cash flow of about $6.5 Billion in 2016. Teva expects a double digit increase in its non-GAAP earnings per share in 2016 due to the acquisition.

Teva is Israel largest drug company and has long been a source of pride for Israelis. The company dates back to 1901, when its founders launched a small importer of medications. According to the company’s website, it began producing drugs in the 1930s.